Immunological investigations · 2025
Emerging Insights into TIM-3: A Potential Immune Checkpoint for Lung Cancer Immunotherapeutic Strategies.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
B Allela Omer Qutaiba, Shareef Abdulkareem, Kumar Bishoyi Ashok, Oweis Rami, Ballal Suhas, Singh Abhayveer, Sinha Aashna, Ray Subhashree, Sameer Hayder Naji, Yaseen Ahmed, Athab Zainab H, Adil Mohaned
Аннотация
BACKGROUND: Recent advancements in cancer therapy have focused on blocking immune checkpoint receptors (ICRs) to restore anti-tumor immunity. Despite these developments, a significant proportion of patients remain unresponsive to currently available immune checkpoint inhibitors (ICIs), highlighting the urgent need for novel therapeutic targets. T-cell immunoglobulin mucin-3 (TIM-3) has emerged as a new immune checkpoint molecule implicated in tumor immune evasion and cancer progression.
METHODS: This review synthesizes data from recent epidemiological and molecular studies examining the role of TIM-3 in lung cancer. The literature related to the genetic mutations, expression patterns, and immunological mechanisms of TIM-3 was systematically analyzed to explore its clinical and therapeutic significance.
RESULTS: The findings indicate that mutations in the TIM-3 gene are correlated with increased susceptibility to lung malignancies. TIM-3 expression is consistently elevated in both tumor cells and immune cells of patients with lung cancer. Evidence further demonstrates that TIM-3 contributes to impaired immune responses, impacts prognostic outcomes, and influences resistance to existing ICIs. These observations suggest that TIM-3 functions as a critical modulator of tumor-immune interactions.
CONCLUSION: TIM-3 represents a promising therapeutic target for overcoming resistance to current immunotherapies and improving clinical outcomes in lung cancer. Understanding the regulatory mechanisms of TIM-3 expression provides valuable insights that may guide the development of future therapeutic strategies and precision medicine approaches.
METHODS: This review synthesizes data from recent epidemiological and molecular studies examining the role of TIM-3 in lung cancer. The literature related to the genetic mutations, expression patterns, and immunological mechanisms of TIM-3 was systematically analyzed to explore its clinical and therapeutic significance.
RESULTS: The findings indicate that mutations in the TIM-3 gene are correlated with increased susceptibility to lung malignancies. TIM-3 expression is consistently elevated in both tumor cells and immune cells of patients with lung cancer. Evidence further demonstrates that TIM-3 contributes to impaired immune responses, impacts prognostic outcomes, and influences resistance to existing ICIs. These observations suggest that TIM-3 functions as a critical modulator of tumor-immune interactions.
CONCLUSION: TIM-3 represents a promising therapeutic target for overcoming resistance to current immunotherapies and improving clinical outcomes in lung cancer. Understanding the regulatory mechanisms of TIM-3 expression provides valuable insights that may guide the development of future therapeutic strategies and precision medicine approaches.